Pneumonia Clinical Trial
— CEFTAREAOfficial title:
Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Normal or Augmented Renal Clearance
NCT number | NCT03025841 |
Other study ID # | CEFTAREA |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | December 2016 |
Est. completion date | June 2018 |
Verified date | March 2019 |
Source | Poitiers University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pneumonia is the most frequent infection in critically ill patients and remains a significant
challenge to intensivists world-wide due to persisting high mortality and morbidity.
Compelling evidence suggests that appropriate antibiotic therapy remains the most important
intervention to improve patients' outcome, including the administration of a suitable
molecule at an optimized dosage regimen. A vast array of pathophysiological changes can occur
in critically ill patients that can complicate antibiotic dosing. Knowledge of the
pharmacokinetic and pharmacodynamic properties of the antibiotics used for the management of
critically ill patients is essential for selecting the antibiotic dosing regimens, which will
optimize patient outcomes. Changes in volume of distribution (Vd) and clearance (CL) of
antibiotics have been noted in these patients, which may affect the antibiotic concentration
at the target site. It follows that the pharmacodynamic parameters that determine antibiotic
efficacy, which can vary between antibiotic classes, may also be affected. Optimization of
these parameters is necessary to maximize the rate of response through patient recovery and
minimized antibiotic resistance.
In a multicenter observational study in critically ill patients with normal plasma renal
indices at admission, about 65% of patients manifested augmented creatinine clearance on at
least one occasion in the first seven study days. Augmented creatinine clearance may
significantly impact drug pharmacokinetics for a variety of renally eliminated
pharmaceuticals (such as low-molecular weight heparins, aminoglycosides, glycopeptides, and
β-lactams), leading to subtherapeutic concentrations and potentially adverse clinical
outcomes. Currently little data exist that describe the consequences of augmented creatinine
clearance on antibiotics PK.
Ceftaroline (600 mg bid) is a cephalosporin with expanded gram-positive activity, including
MRSA and penicillin-resistant streptococcus, which was approved by the US Food and Drug
Administration (FDA) on October 29, 2010 for the treatment of acute bacterial SSSIs and
community-acquired bacterial pneumonia. Ceftaroline showed also good activity against some of
the common gram-negative respiratory pathogens (eg, Haemophilus influenzae, Moraxella
catarrhalis, Neisseria meningitidis, and Pasteurella multocida). However, it does not display
clinically relevant activity against Pseudomonas aeruginosa, Stenotrophomonas maltophilia, or
Acinetobacter baumannii. Ceftaroline also lacks activity against gram-negative organisms with
extended-spectrum β-lactamases. Importantly, because ceftaroline appears to induce AmpC
β-lactamases despite MIC values in susceptible range, ittheoretically should be avoided in
gram-negative bacteria known to harbor inducible AmpC β-lactamases (eg, Serratia, Proteus,
Citrobacter, Morganella, Enterobacter, Providencia, and P. aeruginosa). In patients,
ceftaroline is given as a prodrug, ceftaroline fosamil. After intravenous administration, the
prodrug is rapidly transformed by plasma phosphatase enzymes to its bioactive metabolite. The
pharmacokinetics of ceftaroline has been evaluated in single and multiple dose studies in
healthy volunteers, in subjects with various degrees of renal impairment and in healthy
elderly subjects. The volume of distribution is equal to 20.3 L, which corresponds to
extracellular fluid volume. The protein binding is low (20%). The main route of elimination
is via renal excretion, with a clearance estimated to160 mL/min close to the creatinine
clearance. The elimination half-live is 2.6 h in adults with normal renal function.
Unfortunately, no PK study has been performed in infected critically ill patients with
augmented creatinine clearance. The best PK-PD index predicting drug efficacy is %Time>CMI. A
bacteriostatic effect is achieved when free drug concentrations exceed the MIC for 30 to 40%
of the dose administration interval (30 to 40%T>MIC). Near maximum organism kill is achieved
at 50 to 60%T>MIC (30%T>MIC for Staphylococcus aureus).
This project aims to characterize ceftaroline PK in patients with early-onset pneumonia and
augmented creatinine clearance. The choice of ceftaroline is justified by its spectrum
suitable for micro-organisms commonly encountered in early onset pneumonia, including
methicillin-resistant Staphylococcus aureus. Secondary main objective is to predict the
probably of reaching PK-PD targets using Monte Carlo simulations under various scenario in
order to identify optimal ceftaroline administration schemes in critical care patients with
various degrees of renal impairment.
Status | Completed |
Enrollment | 18 |
Est. completion date | June 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Hospitalized in ICU - Under mechanical ventilation - Developing early-onset (during the seven days following hospital admission) pneumonia caused by Gram positive and/or Gram negative bacteria. - Having an augmented or normal renal clearance defined by a directly measured creatinine clearance, using MD-RD: - normal clearance: between 80 and 130 mL/min/1.73m² - augmented clearance: more than or equal to 130 mL/min/1.73m² Exclusion Criteria: - Having one or more risk factors of multi drug resistant bacteria: - antibiotic treatment in last 3 months - high level resistance in the unit - immunosuppression - one or more pneumonia risks factors, whose one hospitalization of more than 48 hours in past 90 days, - living in medical care house, - chronic hemodialysis, - home based wound care - resistant bacteria in the family environment - Morbidly obese subjects (BMI>40 kg/m²) - Septic shock - Ceftaroline administered in past 14 days before inclusion - Diuretic treatment - Suspicion or confirmation pneumonia ceftaroline-resistant bacteria - Known hypersensitivity due to Ceftaroline or cephalosporin antibiotics - Known hypersensitivity due to Gentamicin or aminoglycosides antibiotics - Hypersensitivity due beta lactamin antibiotics - Anemia |
Country | Name | City | State |
---|---|---|---|
France | CHU poitiers | Poitiers |
Lead Sponsor | Collaborator |
---|---|
Poitiers University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Minimum plasma concentration of Ceftaroline | Day 6 | ||
Primary | Maximum plasma concentration of Ceftaroline | Day 6 | ||
Primary | Volume of distribution of Ceftaroline in plasma | Day 6 | ||
Primary | Clearance of Ceftaroline in plasma | Day 6 | ||
Primary | Elimination half life of Ceftaroline in plasma | Day 6 | ||
Secondary | Pharmacokinetic measures outcomes to obtain the dosing regimens through the monte carlo simulation. | in at least 90% of simulated subjects for minimal inhibitory concentration from 0.008 to 32 mg/L | Day 6 | |
Secondary | Clinical efficacy during Ceftaroline treatment and two weeks after end of it | Patients will be considered to have clinical failure if they will have no response to the study drug on the basis of ongoing signs and symptoms of infection. Otherwise, patients will be considered to have clinical success | Day 28 | |
Secondary | Safety evaluation by adverse events and serious adverse events collection | One month following the last administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Completed |
NCT05815264 -
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
|
Phase 1 | |
Recruiting |
NCT04589936 -
Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care
|
N/A | |
Completed |
NCT02905383 -
The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital
|
N/A | |
Completed |
NCT06210737 -
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years
|
Phase 4 | |
Terminated |
NCT03944551 -
Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa
|
N/A | |
Terminated |
NCT04660084 -
Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Withdrawn |
NCT05702788 -
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04171674 -
Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation.
|
N/A | |
Active, not recruiting |
NCT03140163 -
Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR]
|
N/A | |
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Completed |
NCT02638649 -
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
|
||
Recruiting |
NCT02515565 -
Physiotherapy in Patients Hospitalized Due to Pneumonia.
|
N/A | |
Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
Completed |
NCT01416519 -
Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation
|
N/A | |
Completed |
NCT01399723 -
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
|
Phase 3 | |
Completed |
NCT01446926 -
Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants
|
Phase 1 | |
Terminated |
NCT02358642 -
Drug to Prevent Pneumonia in the Tube Fed
|
Phase 4 | |
Completed |
NCT01416506 -
Community-Acquired Pneumonia (CAP) Surveillance
|
N/A |